Financial Review: Oruka Therapeutics (ORKA) & Its Rivals

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Oruka Therapeutics to related businesses based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, risk, dividends and profitability.

Profitability

This table compares Oruka Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -20.18% -19.51%
Oruka Therapeutics Competitors -1,887.59% -41.66% -26.54%

Valuation and Earnings

This table compares Oruka Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oruka Therapeutics N/A -$5.34 million -4.53
Oruka Therapeutics Competitors $550.52 million $6.13 million -106.30

Oruka Therapeutics’ rivals have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Oruka Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ rivals have a beta of 1.29, indicating that their average share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Oruka Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics 0 0 6 2 3.25
Oruka Therapeutics Competitors 864 811 1351 23 2.17

Oruka Therapeutics currently has a consensus price target of $43.17, suggesting a potential upside of 58.76%. As a group, “Diagnostic substances” companies have a potential upside of 46.86%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than its rivals.

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by company insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Oruka Therapeutics beats its rivals on 10 of the 13 factors compared.

Oruka Therapeutics Company Profile

(Get Free Report)

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.